MUSCAT: Pharmaceutical giant AstraZeneca has “voluntarily paused” a clinical trial of its coronavirus vaccine after a volunteer developed an unexplained illness.
The company, which is developing the drug alongside the University of Oxford in the UK, is a frontrunner in the global race for a COVID-19 vaccine.
“As part of the ongoing randomized, controlled global trials of the Oxford coronavirus vaccine, our standard review process was triggered and we voluntarily paused vaccination to allow review of safety data by an independent committee,” a spokesperson said.
Read More
- Oman Air signs deal to bring 30,000 Indonesian visitors to Salalah in 2027
- Muscat Municipality announces traffic diversions on Al Khuwair road from October 22
- Oman’s Information Ministry to host 2026 Media Excellence Competition awards on October 26
- Oman, UK review military cooperation during His Majesty Sultan Haitham’s state visit
- 30th Muscat International Book Fair set for March 2027 under ‘Creative Industries’ theme
“This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials.”
“We are working to expedite the review of the single event to minimise any potential impact on the trial timeline,” the spokesperson added.
